Compare Scancell Holdings Plc with Similar Stocks
Dashboard
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of 41.69% and Operating profit at -127.24% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -8.38
2
The company declared negative results in Oct'24 after flat results in Apr'24
3
Risky -
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
15.2%
0%
15.2%
6 Months
15.76%
0%
15.76%
1 Year
38.24%
0%
38.24%
2 Years
14.63%
0%
14.63%
3 Years
-30.88%
0%
-30.88%
4 Years
-4.08%
0%
-4.08%
5 Years
-48.91%
0%
-48.91%
Scancell Holdings Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
41.69%
EBIT Growth (5y)
-127.24%
EBIT to Interest (avg)
-8.38
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.40
Sales to Capital Employed (avg)
0.53
Tax Ratio
35.74%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-15.93
EV to EBIT
-10.56
EV to EBITDA
-11.21
EV to Capital Employed
-140.96
EV to Sales
29.92
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
Bullish
Bullish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Apr'25
Apr'25
Apr'24
Change(%)
Net Sales
4.70
0.00
Operating Profit (PBDIT) excl Other Income
-14.10
-17.30
18.50%
Interest
1.70
1.10
54.55%
Exceptional Items
1.80
0.00
Consolidate Net Profit
-12.30
-5.90
-108.47%
Operating Profit Margin (Excl OI)
-3,184.20%
0.00%
-318.42%
USD in Million.
Net Sales
YoY Growth in year ended Apr 2025 is 0.00% vs -100.00% in Apr 2024
Consolidated Net Profit
YoY Growth in year ended Apr 2025 is -108.47% vs 50.42% in Apr 2024
About Scancell Holdings Plc 
Scancell Holdings Plc
Pharmaceuticals & Biotechnology
Scancell Holdings plc is a biopharmaceutical company focused on the cancer therapeutics market. The Company's principal activity consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. The Company is developing a pipeline of immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope platforms. The Company's products include SCIB1, SCIB2 and Modi-1. The Company's first cancer vaccine, SCIB1, is being developed for the treatment of melanoma and is in Phase I/II clinical trials. SCIB2 contains multiple T cell epitopes derived from the lung cancer associated antigen NY-ESO-1. It is developed to the point at which the product is defined and ready for further preclinical development as an immunotherapy for any tumor that expresses the NY-ESO-1 antigen. The Company's first Moditope development candidate is Modi-1. Modi-1 consists of two citrullinated vimentin peptides and one citrullinated enolase peptide.
Company Coordinates 
Company Details
Department of Clinical Oncology, Hucknall Road OXFORD None : OX4 4GP
Registrar Details






